ES2164011B1 - COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. - Google Patents

COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.

Info

Publication number
ES2164011B1
ES2164011B1 ES200000459A ES200000459A ES2164011B1 ES 2164011 B1 ES2164011 B1 ES 2164011B1 ES 200000459 A ES200000459 A ES 200000459A ES 200000459 A ES200000459 A ES 200000459A ES 2164011 B1 ES2164011 B1 ES 2164011B1
Authority
ES
Spain
Prior art keywords
substances
treatment
combined use
tumors
compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES200000459A
Other languages
Spanish (es)
Other versions
ES2164011A1 (en
Inventor
Cuervas-Mons Inigo Narvaiza
Rizzo Guillermo Mazzolini
Bermejo Ignacio Melero
Cheng Qian
Valtuena Jesus Prieto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Instituto Cientifico y Tecnologico de Navarra SA
Original Assignee
Instituto Cientifico y Tecnologico de Navarra SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Instituto Cientifico y Tecnologico de Navarra SA filed Critical Instituto Cientifico y Tecnologico de Navarra SA
Priority to ES200000459A priority Critical patent/ES2164011B1/en
Priority to PCT/ES2001/000066 priority patent/WO2001062274A1/en
Priority to AU2001233811A priority patent/AU2001233811A1/en
Publication of ES2164011A1 publication Critical patent/ES2164011A1/en
Application granted granted Critical
Publication of ES2164011B1 publication Critical patent/ES2164011B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/208—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Uso combinado de la quimiocina IP-10 y la interleucina-12 en la preparación de composiciones para el tratamiento de tumores malignos. La invención se relaciona con el uso combinado de la quimiocina IP-10 y la interleucina-12 como terapia frente a tumores malignos, así como el uso de IP-10 para potenciar el efecto antitumoral de IL-12. Estas dos sustancias son proteínas inmunomoduladoras que potencian la respuesta antitumoral. La administración en mamíferos de ambas sustancias en combinación permite aumentar la actividad anti-tumoral en el mamífero portador del tumor. La administración de ambas sustancias puede realizarse mediante proteína recombinante preparada in-vitro o mediante sistemas de expresión o transferencia génica que expresen dichas sustancias. La combinación de ambas substancias tiene un efecto sinérgico en la inducción de linfocitos citotóxicos específica frente a tumores. La combinación de ambas sustancias, en las proporciones y dosis adecuadas para cada caso, puede ser útilpara el tratamiento de cualquier tipo de cáncer como por ejemplo el adenocarcinoma de colon.Combined use of chemokine IP-10 and interleukin-12 in the preparation of compositions for the treatment of malignant tumors. The invention relates to the combined use of chemokine IP-10 and interleukin-12 as a therapy against malignant tumors, as well as the use of IP-10 to enhance the antitumor effect of IL-12. These two substances are immunomodulatory proteins that enhance the antitumor response. The administration in mammals of both substances in combination allows to increase the anti-tumor activity in the tumor-bearing mammal. The administration of both substances can be carried out by recombinant protein prepared in-vitro or by gene expression or transfer systems expressing said substances. The combination of both substances has a synergistic effect on the induction of specific cytotoxic lymphocytes against tumors. The combination of both substances, in the appropriate proportions and doses for each case, can be useful for the treatment of any type of cancer such as colon adenocarcinoma.

ES200000459A 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS. Expired - Lifetime ES2164011B1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
ES200000459A ES2164011B1 (en) 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.
PCT/ES2001/000066 WO2001062274A1 (en) 2000-02-25 2001-02-22 Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors
AU2001233811A AU2001233811A1 (en) 2000-02-25 2001-02-22 Combined use of chemokine ip-10 and interleukin 12 in the preparation of compositions for the treatment of malignant tumors

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ES200000459A ES2164011B1 (en) 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.

Publications (2)

Publication Number Publication Date
ES2164011A1 ES2164011A1 (en) 2002-02-01
ES2164011B1 true ES2164011B1 (en) 2003-05-16

Family

ID=8492479

Family Applications (1)

Application Number Title Priority Date Filing Date
ES200000459A Expired - Lifetime ES2164011B1 (en) 2000-02-25 2000-02-25 COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.

Country Status (3)

Country Link
AU (1) AU2001233811A1 (en)
ES (1) ES2164011B1 (en)
WO (1) WO2001062274A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7041302B2 (en) * 2001-01-09 2006-05-09 Biother Corporation Therapeutic modulation of the tumor inflammatory response
WO2004062585A2 (en) * 2003-01-07 2004-07-29 Children's Hospital Medical Center Cytokine inhibition of eosinophils
RU2749113C2 (en) 2015-04-22 2021-06-04 Куревак Аг Rna-containing composition for treatment of tumor diseases
JP7246930B2 (en) 2016-05-18 2023-03-28 モデルナティエックス インコーポレイテッド Polynucleotides encoding interleukin-12 (IL12) and uses thereof
MA47680A (en) 2017-02-28 2020-01-08 Sanofi Sa THERAPEUTIC RNA
AU2018270111B2 (en) 2017-05-18 2022-07-14 Modernatx, Inc. Polynucleotides encoding tethered interleukin-12 (IL12) polypeptides and uses thereof
WO2019075452A1 (en) * 2017-10-13 2019-04-18 Evelo Biosciences, Inc. Identification of bacteria for cancer therapy

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5318299A (en) * 1998-07-27 2000-02-21 Valentis, Inc. Anti-angiogenesis plasmids and delivery systems, and methods of making and using the same

Also Published As

Publication number Publication date
ES2164011A1 (en) 2002-02-01
AU2001233811A1 (en) 2001-09-03
WO2001062274A1 (en) 2001-08-30

Similar Documents

Publication Publication Date Title
Whelan et al. The role of interferons in the treatment of osteosarcoma
Sersa et al. Electrochemotherapy with CDDP on LPB sarcoma: comparison of the anti-tumor effectiveness in immunocompotent and immunodeficient mice
Moschella et al. Combination strategies for enhancing the efficacy of immunotherapy in cancer patients
Zhang et al. Anthracyclines potentiate anti-tumor immunity: A new opportunity for chemoimmunotherapy
Wang et al. Interferon: current status and future prospects in cancer therapy
Drozdzik et al. Combined gene therapy with suicide gene and interleukin-12 is more efficient than therapy with one gene alone in a murine model of hepatocellular carcinoma
BR9407956A (en) Pharmaceutical composition vector of recombinant adenovirus expression and kit to reduce tumor cell proliferation
DK1401458T3 (en) Composition consisting of PHY906 and chemotherapeutic agents
BR0113491A (en) Isolated polynucleotide and polypeptide, expression vector, host cell, fusion protein, methods for stimulating and / or expanding tumor protein-specific T cells to stimulate an immune response in a patient, to treat cancer in a patient and to inhibit cancer development in a patient, isolated t-cell population, composition, and use of a component.
NZ226005A (en) Covalent conjugates of a human cytokine and a human immunoglobulin, processes for their manufacture and pharmaceutical compositions thereof
Vasekar et al. Immunotherapy in bladder cancer
ES2134294T3 (en) IMMUNE REACTIVITY FOR EXPRESSIVE ACTIVE ONCOGENS FOR DIAGNOSIS AND TREATMENT OF MALIGNANT TUMORS.
Rekers et al. Combination of radiotherapy with the immunocytokine L19-IL2: Additive effect in a NK cell dependent tumour model
Wang et al. Effect of combined treatment with recombinant interleukin-2 and allicin on pancreatic cancer
Buchbinder et al. Interferon, interleukin-2, and other cytokines
EA200970607A1 (en) UNIVERSAL VACCINE FROM TUMOR CELLS FOR ANTI-CANCER THERAPY AND PREVENTION USE
WO2004096159A3 (en) Saposin c-dops: a novel anti-tumor agent
ES2164011B1 (en) COMBINED USE OF IP-10 CHEMIOKIN AND INTERLEUCINE-12 IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF EVIL TUMORS.
Teicher et al. In vivo studies with Interleukin‐12 alone and in combination with monocyte colony‐stimulating factor and/or fractionated radiation treatment
Teicher et al. Optimal scheduling of interleukin 12 and chemotherapy in the murine MB-49 bladder carcinoma and B16 melanoma.
BR0009170A (en) akt nucleic acids, polypeptides and their use
ATE484290T1 (en) PEPTIDE WITH ANTI-TUMORAL EFFECT
BR0008305A (en) Use of an enterobacterium ompa protein, or one of its fragments and pharmaceutical composition
van Herpen et al. Prognostic and predictive factors of immunotherapy in metastatic renal cell carcinoma
DK1161250T3 (en) Immunostimulatory bacterial membrane fractions in cancer treatment

Legal Events

Date Code Title Description
EC2A Search report published

Date of ref document: 20020201

Kind code of ref document: A1

Effective date: 20020201

FG2A Definitive protection

Ref document number: 2164011B1

Country of ref document: ES

FA2A Application withdrawn

Effective date: 20031120